Galmed Pharmaceuticals Ltd
NASDAQ:GLMD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Xeriant Inc
OTC:XERI
|
US |
Galmed Pharmaceuticals Ltd
Research & Development
Galmed Pharmaceuticals Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Galmed Pharmaceuticals Ltd
NASDAQ:GLMD
|
Research & Development
-$4.9m
|
CAGR 3-Years
28%
|
CAGR 5-Years
28%
|
CAGR 10-Years
4%
|
|
|
Kamada Ltd
NASDAQ:KMDA
|
Research & Development
-$12.2m
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
3%
|
|
|
Enlivex Therapeutics Ltd
NASDAQ:ENLV
|
Research & Development
-$9.6m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-2%
|
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Research & Development
-$67.1m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Research & Development
-$5.5m
|
CAGR 3-Years
8%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Pluri Inc
NASDAQ:PLUR
|
Research & Development
-$15.4m
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
Galmed Pharmaceuticals Ltd
Glance View
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).
See Also
What is Galmed Pharmaceuticals Ltd's Research & Development?
Research & Development
-4.9m
USD
Based on the financial report for Dec 31, 2025, Galmed Pharmaceuticals Ltd's Research & Development amounts to -4.9m USD.
What is Galmed Pharmaceuticals Ltd's Research & Development growth rate?
Research & Development CAGR 10Y
4%
The average annual Research & Development growth rates for Galmed Pharmaceuticals Ltd have been 28% over the past three years , 28% over the past five years , and 4% over the past ten years .
